Pharming Group NV is a global pharmaceutical company in the Netherlands with a risk rating score of 25.4, indicating a medium-risk assessment. Specializing in rare disease treatments, Pharming Group focuses on ESG principles to develop protein replacement therapies and precision medicines, with Ruconest as part of its innovative product portfolio. With a revenue generated mainly from the United States, Pharming Group is dedicated to improving the lives of patients worldwide.